Home > Insider Trading > Filing (0001144204-18-035443)

Filing Details

Accession Number:: 0001144204-18-035443
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-22 19:33:02
Reporting Period:: 2018-06-22

Accepted Time:: 2018-06-22 19:33:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	Yes	No
1346824	Ra Capital Management, Llc	20 Park Plaza, Suite 1200 Boston MA 02116	Yes	No	No	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-22	1,103,847	$0.00	1,103,847	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-06-22	1,058,824	$17.00	2,162,671	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-06-22	922,950	$0.00	1,103,847	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The convertible preferred stock automatically converted to common stock immediately prior to the closing of the Issuer's initial public offering on a 1.196-for-one basis, and had no expiration date.
Includes (a) 898,533 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P.(the "Fund") and (b) 205,314 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser for the Account. Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Dr. Kolchinsky may be deemed indirect beneficial owners of the securities and they disclaim beneficial ownership of the reported securities: (A) in reliance on Rule 16a-1(a)(1)(v) and (vii); and (B) held by the Fund, for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
The Adviser and Dr. Kolchinsky have no pecuniary interest in the reported securities held in the Account and disclaim: (A) beneficial ownership thereof for purposes of Rule 16a-1(a)(2); and (B) any obligation to file reports under Section 16 other than as a director by deputization. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Dr. Kolchinsky is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.
Includes (a) 856,266 shares of Common Stock held by the Fund and (b) 202,558 held in the Account, in each case acquired in the Issuer's initial public offering.
These securities include 1,754,799 shares held by the Fund and 407,872 shares held in the Account.
Represents 751,282 shares of Series B Convertible Preferred Stock held by the Fund and 171,668 shares of Series B Convertible Preferred Stock held in the Account.